Gilles Tamagnan is an associate professor adjunct in psychiatry and research scientist at Xuanwu Hospital in Beijing. He is also CEO of XingImaging. Dr. Tamagnan applies his leadership and expert knowledge to designing and coordinating experiments for the development of radiolabeled tracers into radiopharmaceuticals suitable for use in humans. He is also responsible for the IND submission and working with the clinical team to validate these radiopharmaceuticals. He has more than 20 years of industrial and academic experience in the research and development of radiopharmaceuticals labeled with short-lived gamma-emitting radionuclides. Dr. Tamagnan is an active member of the nuclear medicine research community and has been involved in the evaluation of more than 70 CNS PET and SPECT imaging agents aimed at improving the diagnosis and treatment of neurologic and psychiatric conditions. He is a physician sponsor of more than 35 INDs.